None listed
Conditions
Brief summary
This study is testing a new blood marker for heart cell death called cell free DNA (cfDNA). Drugs like inotropes may cause injury to the heart muscle which current blood markers are unable to detect. We will take samples of blood from heart failure patients admitted to the Coronary Care Unit (CCU) before, during and after the commencement of inotrope treatment, as prescribed by the cardiologist. We will investigate if there is any detectable damage to the heart in association with these medications by measuring the amount of cfDNA in the blood stream.
Interventions
Heart failure patients that have been admitted to the coronary care unit for inotrope administration will have their blood sampled by medical doctors at 4 timepoints; prior to commencing inotropes, 3 hrs post inotrope commencement, 24hrs post inotrope commencement, 24hrs post cessation of inotropes. Each blood sample will take approximately 10 minutes. This is the only requirement of the patient.
Data will be collected by the researcher from electronic hospital records and include
- Demographi
Heart failure patients that have been admitted to the coronary care unit for inotrope administration will have their blood sampled by medical doctors at 4 timepoints; prior to commencing inotropes, 3 hrs post inotrope commencement, 24hrs post inotrope commencement, 24hrs post cessation of inotropes. Each blood sample will take approximately 10 minutes. This is the only requirement of the patient. Data will be collected by the researcher from electronic hospital records and include - Demographic data - Co-morbidities - Diagnosis - medications - Standard of care blood test results (Troponin, creatinine, CRP) - Observations (HR, Bp, etc) - Inotrope requirements (type, dose, length of time on infusion) - Length of hospital stay These will be accessed from Septemeber 2022 to September 2023
Sponsors
Heart and Lung Research Institute WA
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
- Inpatients with FSH Advanced heart failure unit - Consented to study participation - Over 18 years of age -Requiring IV administration of either Noradrenaline Dobutamine Milrinone Levosimendan Adrenaline Isoprenaline
Exclusion criteria
o Intubated at time of inotrope commencement -Post heart transplantation - <48 hrs post PCI or device placement - < 48 hrs post sustained VT or sustained atrial arrhythmias or any arrhythmias requiring DCCV - Recent MI
Outcome results
None listed